Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2024 Filed Aug 16, 2024 20:06 UTC |
Holuka Eugene MyronDirector
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001213900-24-070240 · ownership.xml · derivative · entry 1 Holuka Eugene Myron · CIK 0001678292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-07-05 F1 · derivative.exercise_date: This option, originally issued by Citius Oncology Sub, Inc., is 100% vested. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. Read SEC document |
| August 12, 2024 Filed Aug 30, 2024 20:05 UTC Amendment |
Mazur Leonard LDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 3,700,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001213900-24-074519 · ownership.xml · derivative · entry 1 Mazur Leonard L · CIK 0001463414 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,700,000 Underlying: Common Stock · 3,700,000 shares Expires 2033-07-05 F1 · derivative.exercise_date: This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. F2 · balance_after: This Form 4 has been amended to correct the amount of option shares held by the Reporting Person. Read SEC document |
| August 12, 2024 Filed Aug 30, 2024 20:05 UTC Amendment |
HOLUBIAK MYRON ZDirector
|
GrantStock Option (Right to Buy) · Derivative | 1,500,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001213900-24-074518 · ownership.xml · derivative · entry 1 HOLUBIAK MYRON Z · CIK 0001199080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2033-07-05 F1 · derivative.exercise_date: This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. F2 · balance_after: This Form 4 has been amended to correct the amount of option shares held by the Reporting Person. Read SEC document |
| August 12, 2024 Filed Aug 30, 2024 20:05 UTC Amendment |
Czuczman MyronChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,400,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001213900-24-074517 · ownership.xml · derivative · entry 1 Czuczman Myron · CIK 0001817716 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,400,000 Underlying: Common Stock · 1,400,000 shares Expires 2033-07-05 F1 · derivative.exercise_date: This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. F2 · balance_after: This Form 4 has been amended to correct the amount of option shares held by the Reporting Person. Read SEC document |
| August 12, 2024 Filed Aug 30, 2024 20:05 UTC Amendment |
Bartushak JaimeChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,400,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001213900-24-074516 · ownership.xml · derivative · entry 1 Bartushak Jaime · CIK 0001725077 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,400,000 Underlying: Common Stock · 1,400,000 shares Expires 2033-07-05 F1 · derivative.exercise_date: This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. F2 · balance_after: This Form 4 has been amended to correct the amount of option shares held by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.